NEW FOR 2026: Phase 3 Trial Updates In March 2026 , Eli Lilly released landmark topline results from the TRANSCEND-T2D-1 Phase 3 clinical trial
Amyloid-beta interaction with mitochondria
NAC supplementation raises blood glutathione levels by 30-35% within two weeks of consistent daily intake at 600mg twice daily
Now, theres a new peptide in town: retatrutide
Questions to Discuss With Your Clinician Before starting or refilling Rybelsus, it helps to ask focused questions that connect the medication to your daily routine
The distinctive characteristic of Ipamorelin is its exceptional SELECTIVITY: unlike other GHRPs (GHRP-6, GHRP-2, Hexarelin), Ipamorelin does NOT induce significant increases in prolactin, cortisol, ACTH, or aldosterone at studied therapeutic doses